HK Innoen-AINB Collaborate on Developing 'AI Antibody Drugs'

HK inno.N has partnered with AI-based new drug development company AINB to develop biopharmaceuticals and establish an antigen discovery platform.

HK Innoen (left) and AINB logos
[Photo by each company]

On the 5th, HK inno.N announced that it signed a memorandum of understanding (MOU) with AINB for joint new drug development using AI technology.

HK inno.N plans to conduct joint research aiming to discover new antibody candidates applicable to cell and gene therapy (CGT) development and to build an antigen design platform by utilizing AINB’s AI-based new drug development platform. The discovered antibody candidates will be used to further enhance the functions of CGT such as chimeric antigen receptor (CAR)-T and CAR-NK therapies.

AI-based new drug development is emerging as a new topic, with cases of human clinical trials starting overseas and various large domestic pharmaceutical and bio companies partnering with AI new drug discovery and development firms. However, it is still an early market where no cases have yet been fully designed from the initial stage using AI.

They are also working on building an antigen design platform for vaccine development. Antigens are substances that induce immune responses in the body, including molecules from viruses and bacteria. HK inno.N plans to establish a new antigen design platform based on structure data using AI technology in collaboration with AINB, preparing a system to rapidly develop appropriate vaccines in the event of future pandemics.

Won Sung-yong, Director (Executive Director) of HK inno.N’s Bio Research Center, said, “By utilizing AINB’s AI, we expect to shorten the time required compared to before to secure highly competitive new drug candidates and new technologies.”